Dr Georgia Gliki, Senior Business Manager, LifeArc
James Otter, Ellipson Ltd, Entrepreneur in Residence at the University of Southampton, UK
Community Building, Fundamental Research and Translation in Synthetic Biology at Bristol
Professor Dek Woolfosn, Professor of Chemistry and Biochemistry; Principal Investigator of BrisSynbio; Director of the Bristol BioDesign Institute, University of Bristol
BrisSynBio is one of six BBSRC/EPSRC-funded Synthetic Biology Research Centres established in 2014/15 to nucleate research in synthetic biology across the UK, and to facilitate translating this research. BrisSynBio’s science focuses on fundamental aspects of biomolecular design and engineering and applying these to advance synthetic biology. BrisSynBio created the new post of BrisSynBio Innovation Manager to encourage and oversee the translation of this basic synthetic-biology research into real-life applications in drug discovery, new vaccine platforms, designing novel biomaterials, and biosensor development. To date, this has resulted in four new synthetic biology-based companies, 5 new patent applications, and securing £4.5M of translational funding. In addition, interactions with GSK have led to the award of a Royal Society Entrepreneur in Residence, Dr David Tew, who spends part of his time in Bristol on BrisSynBio’s Innovation Programme. The University has recognised these successes by establishing the Bristol BioDesign Institute.
Innovation and commercialisation for UK PLC
Professor Andrew Hopper CBE FREng FRS, University of Cambridge